Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
08:22
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

13th International Conference on Malignant Lymphoma

 

17-20 June 2015 Lugano
FAQs
   
Discussion forum - 13th International Conference on Malignant Lymphoma
    Topic - Pre-clinical studies

If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER
  
 Thread / Poster  Author  Replies  Last reply
Preclinical evaluation of the novel pleiotropic BCR kinase inhibitor IQS019 in in vitro and in vivo models of B lymphoid neoplasms  Gael Roue 1      6/8/2015 11:11:00 PM  
The BET bromodomain inhibitor OTX015 (MK-8628) affects the expression of microRNAs involved in the pathogenesis of lymphoma: in vitro and in vivo evidence  Afua Adjeiwaa Mensah 1      6/8/2015 10:24:00 PM  
Transcriptomic profiling of response to PI3K inhibition by BKM120 in non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL)  Andrew Evens 1      6/8/2015 6:51:00 PM  
Pixantrone has pre-clinical synergistic activity when combined with targeted agents in diffuse large B-cell lymphoma.  Chiara Tarantelli 1      6/8/2015 5:20:00 PM  
OTX015 (MK-8628) targets genes with high levels of promoter H3K4me3 involved in key signalling pathways in splenic marginal zone lymphoma and mantle cell lymphoma  Chiara Tarantelli 1      6/8/2015 5:04:00 PM  
Pre-clinical lymphoma models show high sensitivity to the small molecule YK-4-279  Elaine Chung 1      6/8/2015 1:37:00 PM  
A variant of obinutuzumab with abolished ADCC, ADCP and CDC is as efficient as rituximab in B cell depletion and antitumor activity  Christian Klein 1      5/23/2015 8:34:00 PM  
       




Most viewed poster for this congress
Poster: 9
Visits: 649
Title: Ibrutinib in combination with Rituximab for Relapsed Mantle Cell Lymphoma: An Update from a Phase II Clinical Trial
Authors: Michael Wang ,
Centre: The University of Texas MD Anderson Cancer Center

Poster most viewed in this topic
Poster: 274
Visits: 159
Title: Novel CD37-Targeting Antibody-Drug Conjugate (ADC), IMGN529, Has Synergistic Activity in Combination with Rituximab in Non-Hodgkin Lymphoma (NHL) Models
Authors: Angela Romanelli , JF Ponte, J Deckert, K OCallaghan, JA Coccia, L Lanieri, S Chicklas, R Ruiz-Soto
Centre: ImmunoGen Inc


 




PosterSessionOnline
Logo Draft
 
Logo Cert